Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breastcancer and lupus nephritis patients

Chirality

Volumn 21, Issue 3, 2009, Pages 383-389

  De Miranda Silva, Carolina ^a   Dumêt Fernandes, Bruno Jose ^a   Marques Pereira, Maria Paula ^a   Da Silva, Lucienir Maria ^a   Donadi, Eduardo Antônio ^a   Do Carmo Silva Matthes, Ângelo ^b   De Andrade, Jurandyr Moreira ^a   Lanchote, Vera Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTRO UNIVERSITÁRIO BARÃO DE MAUÁ   (Brazil)

Author keywords

Breast cancer; Cyclophosphamide enantiomers; LC MS MS; Lupus nephritis; Pharmacokinetics

Indexed keywords

ACETIC ACID ETHYL ESTER; ACETONITRILE; CHLOROFORM; CYCLOPHOSPHAMIDE; FORMIC ACID; PHENAZONE; WATER;

ACCURACY; ADULT; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CASE REPORT; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG HALF LIFE; DRUG ISOLATION; DRUG STRUCTURE; ENANTIOMER; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROTON TRANSPORT; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; STEREOCHEMISTRY; TANDEM MASS SPECTROMETRY;

BLOOD CHEMICAL ANALYSIS; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; KINETICS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 60649120979     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20596     Document Type: Article

References (17)

1. Williams ML, Wainer IW, Granvil CP, Gehrcke B, Bernstein ML, Ducharme MP. Pharmacokinetics of (R)- and (S)- cyclophosphamide and their dechloroethylated metabolites in cancer patients. Chirality 1999;11:301-308.
2. Cox PJ, Farmer PB, Jarman M, Jones M. Observations on the differential metabolism and biological activity of the optical isomers of cyclophosphamide. Biochem Pharmacol 1976;25:993-996.
3. Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, Isaacs R, Mckeage MJ. Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients. Clin Exp Pharmacol Physiol 2004;31:677-682.
4. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 2005;37:611-703.
5. Corlett SA, Chrystyn H. High-performance liquid chromatographic determination of the enantiomers of cyclophosphamide in serum. J Chromatogr B Biomed Appl 1996;682:337-342.
6. Reid JM, Stobaugh JF, Sternson LA. Liquid chromatographic determination of cyclophosphamide enantiomers in plasma by precolumn chiral derivatization. Anal Chem 1989;61:441-446.
7. Williams ML, Wainer IW, Embree L, Granvil CP, Barnett M, Ducharme MP. Enantioselective induction of cyclophosphamide metabolism by phenytoin. Chirality 1999;11:569-574.
8. Holm KA, Kindberg CG, Stobaugh JF, Slavik M, Riley CM. Stereoselective, pharmacokinetics and metabolism of the enantiomers of cyclophosphamide. Biochem Pharmacol 1990;39:1375-1384.
9. Jarman M, Milsted RAV, Smyth JF, Kinas RW, Pankiewicz K, Stecl WJ. Comparative metabolism of 2-[Bis(2-chloroethyl) amino] tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide (Cyclophosphamide) and its enantiomers in humans. Cancer Res 1979;39:2762-2767.
10. Baumann F, Preiss R. Cyclophosphamide and related anticancer drugs. J Chromatogr B Biomed Sci Appl 2001;764:173-192.
11. Sottani C, Turci R, Perbellini L, Minoia C. Liquid-liquid extraction procedure for trace determination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 1998;12:1063-1068.
12. Barbieri A, Sabatini L, Indiveri P, Bonfiglioli R, Lodi V, Violante FS. Simultaneous determination of low levels of methotrexate and Cyclophosphamide in human urine by micro liquid chromatography/ electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2006;20:1889-1893.
13. Kasel D, Jetter A, Harlfinger S, Gebhardt W, Fuhr U. Quantification of Cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2004;18:1472-1478.
14. Sadagopan N, Cohen L, Roberts B, Collard W, Omer C. Liquid chromatography-tandem mass spectrometry quantification of cyclophosphamide and its hydroxyl metabolite in plasma and tissue for determination of tissue distribution. J Chromatogr B Biomed Sci Appl 2001;759:277-284.
15. de Jonge ME, van Dam SM, Hillebrand MJX, Rosing H, Huitema ADR, Rodenhuis S, Beijnen JH. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N′,N″-triethylenethiophosphoramide (thiotepa), and N,N′,N″ -triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 2004; 39:262-271.
16. Masurel D, Wainer IW. Analytical and preparative high-performance liquid chromatographic separation of the enantiomers of ifosfamide, cyclophosphamide trofosfamide and their determination in plasma. J Chromatogr 1989;490:133-143.
17. Baumann F, Lorenz C, Jaehde U, Preiss R. Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;729:297-305.